α-synuclein

Ongoing clinical trials and approved products targeting α-synuclein, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials
5ongoing imaging trials
0approved products

Target note

Full name
α-synuclein aggregates
Nature
Presynaptic protein whose aggregates form Lewy bodies and glial inclusions.
Normal expression
—
Value
The first in vivo diagnosis of synucleinopathies, still at the research stage.
Approaches
[18F]ACI-12589, [18F]MNI-1216 and other candidates.
Indications explored
Multiple system atrophy, Parkinson's disease, dementia with Lewy bodies.
Points of caution
Low target density and coexisting aggregates: specificity remains to be established.

Ongoing imaging trials · 5Open in the radar →

TrialPhaseStatusSponsorCountries
α-synuclein tracersNCT06891703 · Alzheimer's disease and cognitive disordersPhase 1RecruitingAC Immune SA1
α-synuclein tracersNCT07880379 · Parkinson's disease and parkinsonian syndromesPhase 1RecruitingXingImaging, LLC1
MODAG-009-P1-0 · α-synuclein tracersNCT07640555 · Parkinson's disease and parkinsonian syndromesPhase 1RecruitingMODAG GmbH1
α-synuclein tracersNCT06827821 · OtherPhase 1Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology1
PIOSA · α-synuclein tracersNCT07640542 · Parkinson's disease and parkinsonian syndromesPhase 1RecruitingMODAG GmbH1

Cite this page

α-synuclein. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/synuclein/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.